Tricuspid valve replacement using a cryopreserved mitral homograft. Surgical technique and initial results

The surgical management of tricuspid valve endocarditis, especially in patients with positive serology for HIV and hepatitis C, is complicated by the inappropriateness of reconstruction and the late complications of mechanical prostheses and bioprostheses. Late results of mitral homograft replacement of the tricuspid valve have been satisfactory, but evidence of moderate and severe regurgitation appears in some patients. This report presents a novel approach to implantation of a mitral homograft in the tricuspid position.

Five patients with complications of native tricuspid valve endocarditis underwent mitral homograft replacement of the tricuspid valve, the homograft being implanted with the anterior leaflet orientated to the septum, the papillary muscles exteriorized and sutured to the right ventricular wall, the posteromedial muscle anteriorly, and the anterolateral muscle inferiorly. The annular attachment was reinforced with a rigid mitral annuloplasty ring in the anti-anatomical relationship.

There was no early mortality. Among three patients available for echocardiographic assessment during the first year, regurgitation was absent in two cases, and trivial in one case. The latter patient died of a drug overdose after nine months. Two patients required insertion of atrioventricular pacemakers for complete heart block.

This novel extension to the technique of mitral homograft replacement of the tricuspid valve for uncontrollable native endocarditis in drug abusers makes the procedure more technically feasible, and should be considered a procedure of choice.